HK1047451B - 一種改善的，腫瘤消解、非實驗室的hsv菌株及其在治療癌症方面的用途 - Google Patents

一種改善的，腫瘤消解、非實驗室的hsv菌株及其在治療癌症方面的用途

Info

Publication number
HK1047451B
HK1047451B HK02108579.0A HK02108579A HK1047451B HK 1047451 B HK1047451 B HK 1047451B HK 02108579 A HK02108579 A HK 02108579A HK 1047451 B HK1047451 B HK 1047451B
Authority
HK
Hong Kong
Prior art keywords
oncolytic
modified
strain
hsv strain
treating cancer
Prior art date
Application number
HK02108579.0A
Other languages
English (en)
Other versions
HK1047451A1 (en
Inventor
Stuart Coffin Robert
Original Assignee
Biovex Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27447756&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1047451(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0001475A external-priority patent/GB0001475D0/en
Priority claimed from GB0002854A external-priority patent/GB0002854D0/en
Priority claimed from GB0100288A external-priority patent/GB0100288D0/en
Priority claimed from GB0100430A external-priority patent/GB0100430D0/en
Application filed by Biovex Ltd filed Critical Biovex Ltd
Publication of HK1047451A1 publication Critical patent/HK1047451A1/xx
Publication of HK1047451B publication Critical patent/HK1047451B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/869—Herpesviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
HK02108579.0A 2000-01-21 2002-11-28 一種改善的，腫瘤消解、非實驗室的hsv菌株及其在治療癌症方面的用途 HK1047451B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0001475A GB0001475D0 (en) 2000-01-21 2000-01-21 Virus strains
GB0002854A GB0002854D0 (en) 2000-02-08 2000-02-08 Virus strains
GB0100288A GB0100288D0 (en) 2001-01-05 2001-01-05 Virus strains
GB0100430A GB0100430D0 (en) 2001-01-06 2001-01-06 Virus strains
PCT/GB2001/000229 WO2001053506A2 (en) 2000-01-21 2001-01-22 Virus strains for the oncolytic treatment of cancer

Publications (2)

Publication Number Publication Date
HK1047451A1 HK1047451A1 (en) 2003-02-21
HK1047451B true HK1047451B (zh) 2005-03-18

Family

ID=27447756

Family Applications (2)

Application Number Title Priority Date Filing Date
HK02108579.0A HK1047451B (zh) 2000-01-21 2002-11-28 一種改善的，腫瘤消解、非實驗室的hsv菌株及其在治療癌症方面的用途
HK02108740.4A HK1047297B (zh) 2000-01-21 2002-11-30 疱疹病毒株

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK02108740.4A HK1047297B (zh) 2000-01-21 2002-11-30 疱疹病毒株

Country Status (22)

Country Link
US (12) US7063835B2 (zh)
EP (4) EP1568779A1 (zh)
JP (6) JP4921669B2 (zh)
KR (2) KR100802403B1 (zh)
CN (2) CN1418255A (zh)
AT (2) ATE282708T1 (zh)
AU (2) AU2695101A (zh)
BE (1) BE2016C033I2 (zh)
BR (3) BR0107736A (zh)
CA (2) CA2398335C (zh)
CY (2) CY2016020I1 (zh)
DE (2) DE60107203T3 (zh)
DK (2) DK1252322T4 (zh)
ES (2) ES2233600T5 (zh)
FR (1) FR16C0026I2 (zh)
GB (2) GB2375113B (zh)
HK (2) HK1047451B (zh)
IL (4) IL150677A0 (zh)
LU (2) LU93101I2 (zh)
NL (2) NL300820I2 (zh)
PT (1) PT1252322E (zh)
WO (2) WO2001053505A2 (zh)

Families Citing this family (175)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
DE60107203T3 (de) * 2000-01-21 2009-07-23 Biovex Ltd. Herpes-virusstämme für die gentherapie
US7749745B2 (en) * 2001-03-27 2010-07-06 Georgetown University Viral vectors and their use in therapeutic methods
GB0203285D0 (en) 2002-02-12 2002-03-27 Brown Susanne M An herpes simplex virus complex
JP2004099584A (ja) * 2002-05-02 2004-04-02 Keio Gijuku Ｈｓｖを用いた抗腫瘍剤
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
GB0317511D0 (en) 2003-07-25 2003-08-27 Biovex Ltd Viral vectors
GB0326798D0 (en) 2003-11-17 2003-12-24 Crusade Lab Ltd Methods for generating mutant virus
WO2005049846A2 (en) * 2003-11-17 2005-06-02 Crusade Laboratories Limited Mutant herpes simplex virus and use thereof in the treatment of squamous cell cancer
US7897146B2 (en) 2003-11-17 2011-03-01 Crusade Laboratories Limited Treatment using herpes simplex virus
JP5522884B2 (ja) * 2004-03-31 2014-06-18 具紀 藤堂 ウイルス療法の抗癌作用増強剤、癌の予防または治療方法
EP1732614B1 (en) * 2004-04-08 2008-12-24 Sangamo Biosciences Inc. Compositions for treating neuropathic and neurodegenerative conditions
US9273326B2 (en) * 2004-04-30 2016-03-01 The Brigham And Women's Hospital, Inc. Tetracycline-regulated gene expression in HSV-1 vectors
EP3002330A1 (en) * 2005-05-27 2016-04-06 Ospedale San Raffaele S.r.l. Gene vector
US20080008686A1 (en) * 2006-07-10 2008-01-10 The Brigham And Women's Hospital, Inc. Tetracycline repressor regulated oncolytic viruses
US8450106B2 (en) * 2007-10-17 2013-05-28 The Ohio State University Research Foundation Oncolytic virus
US8313896B2 (en) * 2008-04-04 2012-11-20 The General Hospital Corporation Oncolytic herpes simplex virus immunotherapy in the treatment of brain cancer
CA2689707A1 (en) 2009-11-16 2011-05-16 Jean-Simon Diallo Identification of the novel small molecule viral sensitizer vse1 using high-throughput screening
WO2011079073A2 (en) 2009-12-21 2011-06-30 The Brigham And Women's Hospital, Inc. Herpes simplex virus vaccines
CN102146418B (zh) * 2010-02-09 2014-01-15 武汉滨会生物科技有限公司 重组ⅱ型单纯疱疹病毒载体及其制备方法、重组病毒、药物组合物及应用
JPWO2011101912A1 (ja) * 2010-02-19 2013-06-17 国立大学法人 東京大学 組み換えヘルペスウイルス及び組換えヘルペスウイルスを含む医薬組成物
EP2550298B1 (en) 2010-03-23 2015-07-15 The Regents of The University of California Compositions and methods for self-adjuvanting vaccines against microbes and tumors
US20130202639A1 (en) * 2010-03-25 2013-08-08 Konstantin G. Kousoulas Synthetic Herpes Simplex Viruses for Treatment of Cancers
EP2670426B1 (en) 2011-01-31 2017-05-10 The General Hospital Corporation Multimodal trail molecules and uses in cellular therapies
EP2753355B1 (en) 2011-09-08 2018-10-24 New York University Oncolytic herpes simplex virus and therapeutic uses thereof
WO2013052915A2 (en) 2011-10-05 2013-04-11 Genelux Corporation Method for detecting replication or colonization of a biological therapeutic
US20140087362A1 (en) 2012-03-16 2014-03-27 Aladar A. Szalay Methods for assessing effectiveness and monitoring oncolytic virus treatment
US20130280170A1 (en) 2012-04-20 2013-10-24 Aladar A. Szalay Imaging methods for oncolytic virus therapy
EP2877572B1 (en) 2012-07-24 2018-11-28 The General Hospital Corporation Oncolytic virus therapy for resistant tumors
EP3981791A1 (en) * 2012-08-30 2022-04-13 Amgen Inc. A method for treating melanoma using a herpes simplex virus and an immune checkpoint inhibitor
US9605074B2 (en) 2012-08-30 2017-03-28 The General Hospital Corporation Multifunctional nanobodies for treating cancer
WO2014055960A1 (en) 2012-10-05 2014-04-10 Genelux Corporation Energy absorbing-based diagnostic and therapeutic methods employing nucleic acid molecules encoding chromophore-producing enzymes
EP3022307A4 (en) * 2013-07-17 2017-04-19 University of Pittsburgh - Of the Commonwealth System of Higher Education Non-toxic hsv vectors for efficient gene delivery applications and complementing cells for their production
US11097055B2 (en) 2013-10-24 2021-08-24 Amgen Inc. Injector and method of assembly
JP7051293B2 (ja) 2013-10-24 2022-04-11 アムジエン・インコーポレーテツド 温度感知制御を伴う薬剤送達システム
CA2927968C (en) 2013-10-25 2023-02-21 Psioxus Therapeutics Limited Oncolytic adenoviruses armed with heterologous genes
EP3082834B1 (en) 2013-12-11 2020-03-11 The General Hospital Corporation DBA Massachusetts Stem cell delivered oncolytic herpes simplex virus and methods for treating brain tumors
US10238700B2 (en) 2014-01-02 2019-03-26 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
WO2015119906A1 (en) 2014-02-05 2015-08-13 Amgen Inc. Drug delivery system with electromagnetic field generator
MA39818A (fr) 2014-03-30 2017-02-08 Benevir Biopharm Inc Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques
SG11201609219QA (en) 2014-05-07 2016-12-29 Amgen Inc Autoinjector with shock reducing elements
KR102506249B1 (ko) 2014-06-03 2023-03-03 암겐 인코포레이티드 약물 전달 시스템 및 사용 방법
NZ730563A (en) 2014-10-14 2019-05-31 Halozyme Inc Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
CA2957960C (en) 2014-10-14 2023-08-22 Amgen, Inc. Drug injection device with visual and audible indicators
JP6716566B2 (ja) 2014-12-19 2020-07-01 アムジエン・インコーポレーテツド 近接センサ付き薬物送達装置
EP3233159B1 (en) 2014-12-19 2020-03-04 Amgen Inc. Drug delivery device with live button or user interface field
CA2970954C (en) 2015-01-26 2023-10-31 Ottawa Hospital Research Institute Compositions and methods for viral sensitization
ES2748750T3 (es) 2015-02-17 2020-03-17 Amgen Inc Dispositivo de administración de fármacos con sujeción asistida por vacío y/o realimentación
ES2905870T3 (es) 2015-02-27 2022-04-12 Amgen Inc Dispositivo de suministro de fármacos que tiene un mecanismo de protección de aguja con un umbral de resistencia ajustable al movimiento de la protección de aguja
GB201505860D0 (en) 2015-04-07 2015-05-20 Agalimmune Ltd Therapeutic compositions and methods of use for treating cancer
WO2016168601A1 (en) 2015-04-17 2016-10-20 Khalid Shah Agents, systems and methods for treating cancer
PT3288573T (pt) * 2015-04-30 2020-03-25 Psioxus Therapeutics Ltd Adenovírus oncolítico que codifica uma proteína b7
US10967015B2 (en) 2015-06-15 2021-04-06 New York University Method of treatment using oncolytic viruses
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
CN105219738A (zh) * 2015-09-21 2016-01-06 北京神源德生物科技有限公司 重组单纯疱疹病毒及它感染和制备它的宿主细胞以及它们的应用
US20190038713A1 (en) 2015-11-07 2019-02-07 Multivir Inc. Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
US11351308B2 (en) 2015-12-09 2022-06-07 Amgen Inc. Auto-injector with signaling cap
AU2016372576A1 (en) 2015-12-17 2018-06-21 Psioxus Therapeutics Limited Virus encoding an anti-TCR-complex antibody or fragment
US11154661B2 (en) 2016-01-06 2021-10-26 Amgen Inc. Auto-injector with signaling electronics
EP3400292B1 (en) 2016-01-08 2020-08-26 Replimune Limited Use of an oncolytic virus for the treatment of cancer
CN109414487B (zh) 2016-02-19 2022-09-02 复诺健生物科技加拿大有限公司 利用stat1/3抑制剂与溶瘤型疱疹病毒的组合物和方法
EP3721922B1 (en) 2016-03-15 2022-05-04 Amgen Inc. Reducing probability of glass breakage in drug delivery devices
CN117143837A (zh) 2016-03-25 2023-12-01 普瑞菲根公司 高转导hsv载体
KR20230051602A (ko) 2016-04-15 2023-04-18 알파인 이뮨 사이언시즈, 인코포레이티드 Icos 리간드 변이체 면역조절 단백질 및 그의 용도
KR20190006495A (ko) 2016-04-15 2019-01-18 알파인 이뮨 사이언시즈, 인코포레이티드 Cd80 변이체 면역조절 단백질 및 그의 용도
EP3426272A4 (en) * 2016-04-26 2020-03-04 Salk Institute for Biological Studies HSV-1 ONCOLYTIC VIRUS THERAPIES THAT TARGET ALT-DEPENDENT CANCERS
CN115960966A (zh) 2016-04-29 2023-04-14 复诺健生物科技加拿大有限公司 在癌细胞中具有增强复制的hsv载体
WO2017189089A1 (en) 2016-04-29 2017-11-02 Amgen Inc. Drug delivery device with messaging label
WO2017192287A1 (en) 2016-05-02 2017-11-09 Amgen Inc. Syringe adapter and guide for filling an on-body injector
AU2017263558B2 (en) 2016-05-13 2022-12-22 Amgen Inc. Vial sleeve assembly
US11238150B2 (en) 2016-05-16 2022-02-01 Amgen Inc. Data encryption in medical devices with limited computational capability
US11541176B2 (en) 2016-06-03 2023-01-03 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
WO2018004842A1 (en) 2016-07-01 2018-01-04 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
WO2018022945A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd112 variant immunomodulatory proteins and uses thereof
CN110088127A (zh) 2016-07-28 2019-08-02 高山免疫科学股份有限公司 Cd155变体免疫调节蛋白及其用途
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
AU2017305335B2 (en) 2016-08-01 2021-11-18 Virogin Biotech Canada Ltd Oncolytic herpes simplex virus vectors expressing immune system-stimulatory molecules
US20190328965A1 (en) 2016-08-17 2019-10-31 Amgen Inc. Drug delivery device with placement detection
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
CA3034983A1 (en) 2016-10-03 2018-04-12 Ottawa Hospital Research Institute Compositions and methods for enhancing growth, spread, and oncolytic and immunotherapeutic efficacy of oncolytic rna viruses
WO2018075447A1 (en) 2016-10-19 2018-04-26 The Trustees Of Columbia University In The City Of New York Combination of braf inhibitor, talimogene laherparepvec, and immune checkpoint inhibitor for use in the treatment cancer (melanoma)
AU2017345764A1 (en) 2016-10-20 2019-05-02 Alpine Immune Sciences, Inc. Secretable variant immunomodulatory proteins and engineered cell therapy
US20200261643A1 (en) 2016-10-25 2020-08-20 Amgen Inc. On-body injector
WO2018111902A1 (en) 2016-12-12 2018-06-21 Multivir Inc. Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
US11298420B2 (en) 2016-12-21 2022-04-12 Memgen, Llc Armed oncolytic viruses
JP2020504767A (ja) 2016-12-21 2020-02-13 メムゲン，エルエルシー 武装した複製可能な腫瘍溶解性アデノウイルス
AU2018210301A1 (en) 2017-01-17 2019-08-01 Amgen Inc. Injection devices and related methods of use and assembly
CN110546265A (zh) 2017-02-09 2019-12-06 因达普塔治疗公司 工程化自然杀伤(nk)细胞及其组合物和方法
AU2018221351B2 (en) 2017-02-17 2023-02-23 Amgen Inc. Insertion mechanism for drug delivery device
JP7064501B2 (ja) 2017-02-17 2022-05-10 アムジエン・インコーポレーテツド 無菌流体流路を備える薬物送達デバイスおよび関連する組立方法
CA3050927A1 (en) 2017-03-06 2018-09-13 Brian Stonecipher Drug delivery device with activation prevention feature
IL268478B2 (en) 2017-03-07 2023-10-01 Amgen Inc Inserting a needle using super pressure
JP2020509837A (ja) 2017-03-09 2020-04-02 アムジエン・インコーポレーテツド 薬剤送達装置のための挿入機構
WO2018170133A1 (en) 2017-03-15 2018-09-20 Amgen Inc. Use of oncolytic viruses, alone or in combination with a checkpoint inhibitor, for the treatment of cancer
AU2018235838B2 (en) 2017-03-16 2023-12-14 Alpine Immune Sciences, Inc. CD80 variant immunomodulatory proteins and uses thereof
US11732022B2 (en) 2017-03-16 2023-08-22 Alpine Immune Sciences, Inc. PD-L2 variant immunomodulatory proteins and uses thereof
EP3596116B1 (en) 2017-03-16 2023-09-06 Alpine Immune Sciences, Inc. Pd-l1 variant immunomodulatory proteins and uses thereof
CN110446512B (zh) 2017-03-28 2022-03-18 美国安进公司 柱塞杆和注射器组件系统以及方法
JP2020517715A (ja) 2017-04-28 2020-06-18 メルク・シャープ・エンド・ドーム・コーポレイション がん療法のためのバイオマーカー
CN106974942A (zh) * 2017-05-03 2017-07-25 武汉滨会生物科技股份有限公司 重组溶瘤ii型单纯疱疹病毒在制备抗淋巴瘤、食道癌、乳腺癌、胰腺癌药物中的应用
EP3634546A1 (en) 2017-06-08 2020-04-15 Amgen Inc. Torque driven drug delivery device
US11590294B2 (en) 2017-06-08 2023-02-28 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
CN107354136A (zh) * 2017-06-15 2017-11-17 杭州睿可特生物科技有限公司 重组单纯疱疹病毒及其制备方法和应用
MX2019015472A (es) 2017-06-22 2020-02-19 Amgen Inc Reduccion del impacto/choque de la activacion del mecanismo.
WO2018237225A1 (en) 2017-06-23 2018-12-27 Amgen Inc. ELECTRONIC DRUG DELIVERY DEVICE COMPRISING A CAP ACTIVATED BY A SWITCH ASSEMBLY
EP3651832B1 (en) 2017-07-14 2023-12-13 Amgen Inc. Needle insertion-retraction system having dual torsion spring system
MA49626A (fr) 2017-07-21 2020-05-27 Amgen Inc Élément d'étanchéité perméable aux gaz pour récipient à médicament et procédés d'assemblage
WO2019022951A1 (en) 2017-07-25 2019-01-31 Amgen Inc. DRUG DELIVERY DEVICE WITH GEAR MODULE AND ASSEMBLY METHOD THEREOF
WO2019022950A1 (en) 2017-07-25 2019-01-31 Amgen Inc. DRUG DELIVERY DEVICE WITH CONTAINER ACCESS SYSTEM AND ASSEMBLY METHOD THEREOF
CR20200099A (es) 2017-08-03 2020-07-24 Amgen Inc Muteínas de interleucina 21 y métodos de tratamiento
JP2020530003A (ja) 2017-08-07 2020-10-15 アムジェン インコーポレイテッド 抗ｐｄ−ｌ１抗体及び腫瘍溶解性ウイルスでの、肝転移を伴う三種陰性乳がん又は結腸直腸がんの処置
EP3664863A2 (en) 2017-08-09 2020-06-17 Amgen Inc. Hydraulic-pneumatic pressurized chamber drug delivery system
MA49897A (fr) 2017-08-18 2020-06-24 Amgen Inc Injecteur sur-corps avec patch adhésif stérile
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
SG11202001499WA (en) 2017-09-08 2020-03-30 Amgen Inc Inhibitors of kras g12c and methods of using the same
US20200308550A1 (en) 2017-09-11 2020-10-01 Imba - Institut Für Molekulare Biotechnologie Gmbh Tumor organoid model
WO2019070472A1 (en) 2017-10-04 2019-04-11 Amgen Inc. FLOW ADAPTER FOR MEDICATION DELIVERY DEVICE
CN111132711B (zh) 2017-10-06 2022-07-01 安进公司 带有联锁组件的药物递送装置及相关组装方法
EP3694578A1 (en) 2017-10-09 2020-08-19 Amgen Inc. Drug delivery device with drive assembly and related method of assembly
EP3694870A1 (en) 2017-10-10 2020-08-19 Alpine Immune Sciences, Inc. Ctla-4 variant immunomodulatory proteins and uses thereof
EA202090974A1 (ru) 2017-10-18 2020-08-05 Элпайн Иммьюн Сайенсиз, Инк. Вариантные иммуномодулирующие белки лиганда icos и сопутствующие композиции и способы
CA3075294A1 (en) 2017-10-27 2019-05-02 Merck Sharp & Dohme Corp. Compositions and methods for treating liver cancer
WO2019090079A1 (en) 2017-11-03 2019-05-09 Amgen Inc. System and approaches for sterilizing a drug delivery device
WO2019089178A1 (en) 2017-11-06 2019-05-09 Amgen Inc. Drug delivery device with placement and flow sensing
WO2019090303A1 (en) 2017-11-06 2019-05-09 Amgen Inc. Fill-finish assemblies and related methods
CA3079665A1 (en) 2017-11-10 2019-05-16 Amgen Inc. Plungers for drug delivery devices
WO2019099324A1 (en) 2017-11-16 2019-05-23 Amgen Inc. Door latch mechanism for drug delivery device
SG11202006148UA (en) 2018-01-03 2020-07-29 Alpine Immune Sciences Inc Multi-domain immunomodulatory proteins and methods of use thereof
CR20200330A (es) 2018-01-12 2020-12-23 Amgen Inc Anticuerpos anti-pd-1 y métodos de tratamiento
US11390650B2 (en) 2018-02-05 2022-07-19 The Brigham And Women's Hospital, Inc. Recombinant Herpes Simplex Virus-2 expressing glycoprotein B and D antigens
EP3768698A4 (en) 2018-03-19 2022-03-30 MultiVir Inc. METHODS AND COMPOSITIONS COMPRISING TUMOR SUPPRESSIVE GENE THERAPY AND CD122/CD132 AGONISTS FOR THE TREATMENT OF CANCER
EP3774877A1 (en) * 2018-03-28 2021-02-17 Bioxodes Anticoagulant fusion proteins and uses thereof
WO2019213305A1 (en) * 2018-05-01 2019-11-07 Albert Einstein College Of Medicine HSV-2-DELTA-gD VACCINES AND METHODS FOR THEIR PRODUCTION AND USE
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
US11505782B2 (en) 2018-06-04 2022-11-22 Calidi Biotherapeutics, Inc. Cell-based vehicles for potentiation of viral therapy
CN112533621A (zh) 2018-06-04 2021-03-19 卡利迪生物治疗有限公司 强化病毒疗法的基于细胞的媒介
KR20210022547A (ko) * 2018-06-08 2021-03-03 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 암 면역 치료를 위한 재조합 단순 헤르페스 바이러스
US20210253655A1 (en) * 2018-06-15 2021-08-19 Children's Hospital Medical Center Polypeptides, nucleic acid molecules, compositions, and related methods
WO2019241758A1 (en) 2018-06-15 2019-12-19 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof
WO2020023220A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation
EP3826701A1 (en) 2018-07-24 2021-06-02 Amgen Inc. Delivery devices for administering drugs
US20210228815A1 (en) 2018-07-24 2021-07-29 Amgen Inc. Hybrid drug delivery devices with grip portion
CA3103682A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Delivery devices for administering drugs
EP3829692A1 (en) 2018-07-31 2021-06-09 Amgen Inc. Fluid path assembly for a drug delivery device
CN109161561A (zh) * 2018-08-09 2019-01-08 湖北科技学院 一种选择性杀灭前列腺癌细胞的新型溶瘤病毒及其构建方法
EP3844276A2 (en) 2018-08-28 2021-07-07 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
MA53724A (fr) 2018-09-24 2021-12-29 Amgen Inc Systèmes et procédés de dosage interventionnel
AU2019350660A1 (en) 2018-09-28 2021-03-18 Amgen Inc. Muscle wire escapement activation assembly for a drug delivery device
AR116679A1 (es) 2018-10-02 2021-06-02 Amgen Inc Sistemas de inyección para la administración de fármacos con transmisión de fuerza interna
EP3860686A1 (en) 2018-10-05 2021-08-11 Amgen Inc. Drug delivery device having dose indicator
CA3109988A1 (en) 2018-10-15 2020-04-23 Amgen Inc. Platform assembly process for drug delivery device
SG11202103800RA (en) 2018-10-15 2021-05-28 Amgen Inc Drug delivery device having damping mechanism
EP3873566A1 (en) 2018-11-01 2021-09-08 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
MA54057A (fr) 2018-11-01 2022-02-09 Amgen Inc Dispositifs d'administration de médicament à rétraction partielle d'élément d'administration de médicament
WO2020092056A1 (en) 2018-11-01 2020-05-07 Amgen Inc. Drug delivery devices with partial needle retraction
CN113271955A (zh) 2018-11-06 2021-08-17 卡利迪生物治疗有限公司 用于细胞介导的溶瘤病毒疗法的增强的系统
KR20210123289A (ko) 2018-11-21 2021-10-13 인답타 세라뷰틱스 인코포레이티드 자연 살해 세포 서브세트의 증식을 위한 방법 및 관련 조성물 및 방법
TW202038947A (zh) 2018-11-28 2020-11-01 德商創新分子有限責任公司 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑
JP2022510276A (ja) 2018-11-30 2022-01-26 アルパイン イミューン サイエンシズ インコーポレイテッド Ｃｄ８６バリアント免疫調節タンパク質およびその使用
WO2020140012A1 (en) 2018-12-27 2020-07-02 Amgen Inc. Lyophilized virus formulations
CA3176660A1 (en) 2019-02-27 2020-09-03 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
MX2021010458A (es) * 2019-03-05 2021-09-21 Amgen Inc Uso de virus oncoliticos para el tratamiento del cancer.
CN114072517A (zh) * 2019-03-14 2022-02-18 麻省理工学院 工程化的单纯疱疹病毒-1(hsv-1)载体及其用途
TW202102543A (zh) 2019-03-29 2021-01-16 美商安進公司 溶瘤病毒在癌症新輔助療法中之用途
US20220160972A1 (en) 2019-04-24 2022-05-26 Amgen Inc. Syringe sterilization verification assemblies and methods
CA3148261A1 (en) 2019-08-23 2021-03-04 Amgen Inc. Drug delivery device with configurable needle shield engagement components and related methods
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
US20210189427A1 (en) * 2019-12-20 2021-06-24 Krystal Biotech, Inc. Compositions and methods for gene delivery to the airways and/or lungs
JP2023523429A (ja) 2020-04-22 2023-06-05 インダプタ セラピューティクス インコーポレイテッド ナチュラルキラー（ｎｋ）細胞組成物およびそれを生成させるための方法
US20220016191A1 (en) * 2020-07-16 2022-01-20 Massachusetts Institute Of Technology Simultaneous delivery of cancer treatment programs to tumor and immune cells
TW202241479A (zh) 2020-12-30 2022-11-01 美商安迅生物製藥公司 遞送外來抗原之溶瘤病毒及表現靶向外來抗原之嵌合受體之經工程化免疫細胞之組合療法
WO2022170219A1 (en) 2021-02-05 2022-08-11 Iovance Biotherapeutics, Inc. Adjuvant therapy for cancer
WO2022246055A1 (en) 2021-05-21 2022-11-24 Amgen Inc. Method of optimizing a filling recipe for a drug container
CN115707781A (zh) * 2021-08-20 2023-02-21 广东东阳光药业有限公司 Hsv病毒载体及其应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5163949A (en) * 1990-03-02 1992-11-17 Bonutti Peter M Fluid operated retractors
US6610287B1 (en) 1990-04-16 2003-08-26 The General Hospital Corporation Transfer and expression of gene sequences into nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
US5328688A (en) 1990-09-10 1994-07-12 Arch Development Corporation Recombinant herpes simplex viruses vaccines and methods
GB9102126D0 (en) 1991-01-31 1991-03-13 Smithkline Beecham Biolog Novel vaccine
GB9202933D0 (en) 1992-02-12 1992-03-25 Smithkline Beecham Biolog Vaccines
EP0675961B1 (en) 1992-03-31 2002-11-27 Arch Development Corporation Treatment of tumorigenic disease with a modified HSV
GB9325496D0 (en) 1993-12-14 1994-02-16 Smithkline Beecham Biolog Vaccines
US5585096A (en) * 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
US5728379A (en) 1994-06-23 1998-03-17 Georgetown University Tumor- or cell-specific herpes simplex virus replication
GB9423663D0 (en) * 1994-11-23 1995-01-11 Cantab Pharma Res Viral preparations, immunogens, and vaccines
NL9500216A (nl) * 1995-02-06 1996-09-02 Bio Pharma Sciences Bv Farmaceutische samenstelling voor de behandeling van herpes.
EP1683858A3 (en) * 1995-02-21 2006-08-02 Cantab Pharmaceuticals Research Limited Viral preparations, vectors, immunogens, and vaccines
ZA966287B (en) 1995-07-27 1998-03-09 American Cyanamid Co Avirulent herpetic viruses useful as tumoricidal agents and vaccines.
US6344445B1 (en) * 1995-10-19 2002-02-05 Cantab Pharmaceutical Research Limited Herpes virus vectors and their uses
GB9524973D0 (en) * 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
WO1997026904A1 (en) 1996-01-25 1997-07-31 Medical Research Council Treatment of non-neuronal cancer using hsv mutant
US5824318A (en) 1996-07-24 1998-10-20 American Cyanamid Company Avirulent herpetic viruses useful as tumoricidal agents and vaccines
GB9615794D0 (en) 1996-07-26 1996-09-04 Medical Res Council Mutant herpes simplex virus strains and uses thereof
US5876923A (en) * 1996-07-26 1999-03-02 Arch Development Corporation Herpes simplex virus ICP4 as an inhibitor of apoptosis
GB2322130B (en) 1997-02-13 2000-12-20 Secr Defence A vaccine against Simian Herpes B virus
GB9704046D0 (en) * 1997-02-27 1997-04-16 Univ Leeds Arrestable therapeutic
US6051428A (en) * 1997-03-21 2000-04-18 Sloan-Kettering Institute For Cancer Research Rapid production of autologous tumor vaccines
US5998174A (en) 1997-05-12 1999-12-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Multigene vectors
US6379674B1 (en) * 1997-08-12 2002-04-30 Georgetown University Use of herpes vectors for tumor therapy
US20030044384A1 (en) * 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
GB9801930D0 (en) 1998-01-29 1998-03-25 Univ London Mutant herpes simplex viruses and uses thereof
CA2323067A1 (en) 1998-03-12 1999-09-16 The Trustees Of The University Of Pennsylvania Producer cells for replication selective viruses in the treatment of malignancy
GB9810904D0 (en) 1998-05-20 1998-07-22 Univ London Mutant herpes simplex viruses and uses thereof
US6713067B2 (en) * 1998-07-31 2004-03-30 Biovex Limited Herpes viruses for immune modulation
GB9816781D0 (en) * 1998-07-31 1998-09-30 Univ London Herpes virus vectors for dendritic cells
EP1102790B1 (en) 1998-08-07 2014-05-07 University of Washington Immunological Herpes Simplex Virus antigens and methods for use thereof
EP1141338A4 (en) 1998-12-31 2002-09-25 Arch Dev Corp RECOMBINANT HERPES SIMPLEX VIRUS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES
US6428968B1 (en) * 1999-03-15 2002-08-06 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
WO2000075292A1 (en) 1999-06-08 2000-12-14 Uab Research Foundation Herpes simplex virus expressing foreign genes and method for treating cancers therewith
US6764675B1 (en) * 1999-06-08 2004-07-20 The Uab Research Foundation Herpes simplex virus expressing foreign genes and method for treating cancers therewith
IL131212A0 (en) * 1999-08-03 2001-01-28 Yissum Res Dev Co Recombinant virus and live-virus vaccines
GB9930419D0 (en) 1999-12-22 2000-02-16 Neurovex Ltd Replication incompetent herpes virus vectors
GB9930418D0 (en) 1999-12-22 2000-02-16 Neurovex Ltd Replication incompetent herpes virus vectors
GB0001476D0 (en) 2000-01-21 2000-03-15 Neurovex Ltd Herpes virus strains
DE60107203T3 (de) * 2000-01-21 2009-07-23 Biovex Ltd. Herpes-virusstämme für die gentherapie
US7063851B2 (en) 2000-04-12 2006-06-20 Biovex Limited Herpes viruses for immune modulation
GB0317511D0 (en) * 2003-07-25 2003-08-27 Biovex Ltd Viral vectors
EP3400292B1 (en) * 2016-01-08 2020-08-26 Replimune Limited Use of an oncolytic virus for the treatment of cancer

Also Published As

Publication number Publication date
US20030113348A1 (en) 2003-06-19
WO2001053505A2 (en) 2001-07-26
CA2398335C (en) 2010-12-07
HK1047297B (zh) 2004-10-21
CY2016021I2 (el) 2016-12-14
GB0219033D0 (en) 2002-09-25
LU93100I2 (fr) 2016-08-08
US20070003571A1 (en) 2007-01-04
BRPI0107737B1 (pt) 2016-11-16
KR20020080383A (ko) 2002-10-23
US8277818B2 (en) 2012-10-02
US20070264282A1 (en) 2007-11-15
EP1252323A2 (en) 2002-10-30
ES2233600T5 (es) 2009-06-22
AU2001226951B8 (en) 2006-10-26
JP2015221813A (ja) 2015-12-10
JP2019048864A (ja) 2019-03-28
ATE312189T1 (de) 2005-12-15
GB2375113A (en) 2002-11-06
CN1425073A (zh) 2003-06-18
IL150678A (en) 2008-12-29
US20200032218A1 (en) 2020-01-30
JP2012072156A (ja) 2012-04-12
DE60107203T3 (de) 2009-07-23
BRPI0107736B1 (pt) 2019-12-17
CA2398343A1 (en) 2001-07-26
WO2001053505A3 (en) 2001-12-27
KR20030032913A (ko) 2003-04-26
WO2001053506A3 (en) 2002-05-23
DE60115600T2 (de) 2006-07-20
BR0107737A (pt) 2002-11-19
WO2001053506A2 (en) 2001-07-26
HK1047451A1 (en) 2003-02-21
US8680068B2 (en) 2014-03-25
CN1250732C (zh) 2006-04-12
AU2694701A (en) 2001-07-31
ES2254359T3 (es) 2006-06-16
AU2001226951B2 (en) 2006-10-05
JP4810042B2 (ja) 2011-11-09
GB2374873B (en) 2004-05-26
JP6644378B2 (ja) 2020-02-12
IL150677A0 (en) 2003-02-12
JP2017132779A (ja) 2017-08-03
US20140154216A1 (en) 2014-06-05
ATE282708T1 (de) 2004-12-15
IL150678A0 (en) 2003-02-12
BRPI0107737B8 (pt) 2021-05-25
EP1252323B1 (en) 2005-12-07
GB2374873C (en) 2011-07-27
PT1252322E (pt) 2005-03-31
DK1252322T3 (da) 2005-03-14
DE60115600D1 (de) 2006-01-12
US20120321599A1 (en) 2012-12-20
IL150677A (en) 2008-12-29
BR0107736A (pt) 2002-11-19
DE60107203T2 (de) 2005-12-01
AU2695101A (en) 2001-07-31
KR100802403B1 (ko) 2008-02-13
US20090220460A1 (en) 2009-09-03
KR100768408B1 (ko) 2007-10-18
GB2374873A (en) 2002-10-30
DK1252322T4 (da) 2009-06-08
EP1252322B1 (en) 2004-11-17
JP2003520044A (ja) 2003-07-02
US7063835B2 (en) 2006-06-20
CY2016020I2 (el) 2016-12-14
US20140154215A1 (en) 2014-06-05
CA2398335A1 (en) 2001-07-26
NL300821I2 (zh) 2016-10-27
US20030091537A1 (en) 2003-05-15
CY2016020I1 (el) 2016-12-14
FR16C0026I2 (fr) 2018-04-27
CY2016021I1 (el) 2016-12-14
JP4921669B2 (ja) 2012-04-25
JP2003520789A (ja) 2003-07-08
LU93101I2 (fr) 2016-08-08
US20200032219A1 (en) 2020-01-30
JP6424145B2 (ja) 2018-11-14
BRPI0107736B8 (pt) 2021-05-25
GB0219030D0 (en) 2002-09-25
AU782659B2 (en) 2005-08-18
EP1252322A2 (en) 2002-10-30
US20120164108A1 (en) 2012-06-28
US7223593B2 (en) 2007-05-29
HK1047297A1 (en) 2003-02-14
EP1252322B2 (en) 2009-03-04
EP1568779A1 (en) 2005-08-31
GB2375113B (en) 2004-10-20
US20150232812A1 (en) 2015-08-20
DK1252323T3 (da) 2006-04-03
BE2016C033I2 (zh) 2020-05-20
US10301600B2 (en) 2019-05-28
CN1418255A (zh) 2003-05-14
DE60107203D1 (de) 2004-12-23
NL300820I2 (zh) 2016-11-17
FR16C0026I1 (zh) 2016-07-22
US7537924B2 (en) 2009-05-26
ES2233600T3 (es) 2005-06-16
EP2177619A1 (en) 2010-04-21

Similar Documents

Publication Publication Date Title
GB2375113B (en) A modified, oncolytic, non-laboratory HSV strain and its use in treating cancer
BR9912671A (pt) Antìgenos imunológicos para o vìrus de herpes simples e métodos para sua utilização
BR0014408A (pt) Antìgenos do vìrus do herpes simples imunologicamente significativos; e métodos para identificação e utilização dos mesmos
WO2003082200A3 (en) Potent oncolytic herpes simplex virus for cancer therapy
ES2134346T3 (es) Virus citopatico para el tratamiento y la profilaxis de la neoplasia.
BR9712366A (pt) Gene de gd2 do vírus do herpes simples hsv2 isolado, plasmídeo compreendendo o mesmo, e, processos de induzir, em indivíduo, uma resposta imune contra hsv2 gd2, de tratar um indíviduo que está infectado com hsv, e, de prevenir que um indivíduo fique infectado com hsv
AU1550797A (en) Treatment of non-neuronal cancer using hsv mutant
PT98565A (pt) Um processo de producao de uma composicao para o tratamento da infeccao por hsv
AU688101B2 (en) Live vaccine for the treatment of tumour diseases
ES2141093T3 (es) Herpesvirus equinos (ehv) que contienen adn ajeno, procedimiento para su obtencion y su empleo en vacunas.
EP1550449A4 (en) ANTITUMORAL AGENTS WITH HSV
WO2003045428A3 (de) Verwendung einer technisch veränderten zelle als vakzine zur behandlung einer tumorerkrankung
Saran et al. Palliative treatment of AIDS-associated kaposi's sarcoma by radiotherapy
AU630099B2 (en) Non-reverting rna viruses

Legal Events

Date Code Title Description
CHPA Change of a particular in the register (except of change of ownership)